Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 16, 2025
Daily News
January 16, 2025
- Minimum NHI Prices to Be Raised by 3% Across the Board on April 1
January 16, 2025
- J-TEC, Kobe Cell Therapy Player Form Capital Alliance
January 16, 2025
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- AnGes Partners with Stanford on Cancer Therapy Research
January 16, 2025
- Mochida to File Actemra Biosimilar in Japan
January 16, 2025
- 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums
January 16, 2025
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…